Q-omics provides the consensus-scored FKBP8 profile across patient tissues and cancer cell-line models. FKBP8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FKBP8 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, FKBP8 protein abundance shows 21,475 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, LIHC, and GBM as cancer lineages where FKBP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FKBP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FKBP8 survival associations across molecular data types. FKBP8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FKBP8 RNA expression–survival associations across cancer types. High FKBP8 expression shows unfavorable associations in COAD, ACC, READ and LIHC, but favorable associations in UCEC and SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FKBP8 RNA expression.
This table summarizes FKBP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FKBP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FKBP8 shows lower tumor expression in LUAD and KICH and higher tumor expression in LIHC, KIRC, HNSC and COAD. The LIHC box plot shows higher FKBP8 RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with FKBP8 in patient tissues and cancer cell lines. In patient samples, FKBP8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FKBP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
